Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706768 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL10703967 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL11575917 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL6558551 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL11802701 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL6558567 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL10627894 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL16583109 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL236570 | 1.00 | — | — | |
| SCHEMBL6262470 | 1.00 | TSHR (0.48) | TSHRDNM1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | claimed |
| WO-2024183010-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | 中国科学院过程工程研究所 | 2024-09-12 | — | — | WO | claimed |
| CN-117479964-A | Tissue-selective single-component mRNA delivery vector and delivery system | 中国科学院过程工程研究所 | 2024-01-30 | — | — | CN | claimed |
| US-10543454-B2 | Carbon dioxide absorbent | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2020-01-28 | — | — | US | claimed |
| US-20180257023-A1 | CARBON DIOXIDE ABSORBENT | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2018-09-13 | — | — | US | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | claimed |
| EP-0644887-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID. | SMITHKLINE BEECHAM PLC (GB) | 1995-03-29 | — | — | EP | claimed |
| WO-1993025557-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1993-12-23 | — | — | WO | claimed |
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | disclosed |
| WO-2024183010-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | 中国科学院过程工程研究所 | 2024-09-12 | — | — | WO | disclosed |
| CN-117479964-A | Tissue-selective single-component mRNA delivery vector and delivery system | 中国科学院过程工程研究所 | 2024-01-30 | — | — | CN | disclosed |
| WO-1993025557-A1 | PROCESS FOR THE PREPARATION OF CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1993-12-23 | — | — | WO | disclosed |
| US-4285874-A | PHOSGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
| EP-0009700-A1 | Process for the preparation 1-isocyanato-anthraquinones | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TSHR 2848/4885DNM1 1620/4885MEN1 4129/4885 |
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | SLC43A1, LNPEP, TLR3 | TSHR 3014/4885DNM1 4538/4885MEN1 4368/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TSHR 3761/4885DNM1 712/4885MEN1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.